雾化吸入在慢性阻塞性肺疾病中的应用

Budesonide and β_2 Agonist Inhalation in Chronic Obstructive Pulmonary Disease with Acute Exacerbation

目的探讨布地奈德混悬液(普米克令舒)与β2受体激动剂(博利康尼)联合雾化吸入治疗慢性阻塞性肺疾病急性加重期(AECOPD)的临床疗效。方法选择我院2006年1月至2008年6月入院的符合标准的60例AECOPD患者,随即分为观察组(布地奈德+β2受体激动剂)和对照组。两组均采用常规治疗,如避免吸烟,预防呼吸道感染,袪痰、止咳对症等治疗,治疗组在上述综合性治疗的基础上,加用布地奈德混悬液和β2受体激动剂吸入治疗。观察治疗前、治疗3d、治疗7d临床症状评分,第一秒用力呼吸容积占预计值的百分比(FEV1%)和激素的不良反应,患者临床疗效。结果两组患者治疗前临床症状评分均较高,各组间无明显差异,FEV1%均较低。组间比较无统计学意义(P>0.05)。治疗后治疗组的总有效率显著高于对照组,两组疗效比较差异有显著性意义(P<0.01);治疗组的FEV1、FVC治疗后显著高于对照组(P<0.05)。结论博利康尼液与普米克令舒联合吸入治疗AECOPD可更好控制症状?改善肺功能、延缓病情恶化过程、提高生活质量。

Objective To investigate clinical efficacy of Budesonide suspension （Pulmicort） and β2 agonist （Bricanyl） United aerosol inhalation in the treatment of chronic obstructive pulmonary disease with acute exacerbation （AECOPD） . Methods Hospital from January 2006 to June 2008 in line with the standards of admission 60 cases of patients with AECOPD, then divided into two groups （budesonide β2 agonist） and the control group. The two groups using conventional way such as avoid smoking, to prevent respiratory tract infection, expectorate, such as cough symptomatic treatment, the treatment group based on the above -mentioned comprehensive treatment plus budesonide suspension and β2 agonist inhalation therapy. To observe clinical symptoms score of three days of treatment, seven - day treatment, forced breath volume in the first second is expected to account the percentage of the value （ FEV1% ） and hormonal side effects, clinical efficacy in patients. Results Clinical symptoms of patients before treatment have a higher score, there was no significant difference between groups, FEV1% were lower. Difference between the groups was not significant （ P 〉 0. 05 ）. After treatment in the treatment group, the total effective rate significantly higher, efficacy difference between the two groups was significant （ P 〈 0.01 ） ; treatment group FEV1, FVC after treatment significantly higher （P 〈 0.05 ）. Conclusion Bricanyl liquid and the United Pulmicort inhalation in therapy of AECOPD can better control the symptoms ,improve lung function, slow the deterioration of the disease process, improve the quality of life.